Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) Operating Income (2018 - 2026)

Exagen filings provide 9 years of Operating Income readings, the most recent being -$3.4 million for Q1 2026.

  • On a quarterly basis, Operating Income fell 1.46% to -$3.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$14.1 million, a 0.86% decrease, with the full-year FY2025 number at -$14.1 million, down 3.18% from a year prior.
  • Operating Income hit -$3.4 million in Q1 2026 for Exagen, up from -$5.0 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$2.6 million in Q2 2024 to a low of -$14.5 million in Q4 2022.
  • Median Operating Income over the past 5 years was -$4.9 million (2023), compared with a mean of -$5.9 million.
  • Biggest five-year swings in Operating Income: plummeted 144.93% in 2022 and later surged 65.05% in 2023.
  • Exagen's Operating Income stood at -$14.5 million in 2022, then surged by 64.48% to -$5.1 million in 2023, then soared by 34.27% to -$3.4 million in 2024, then crashed by 47.06% to -$5.0 million in 2025, then soared by 31.38% to -$3.4 million in 2026.
  • The last three reported values for Operating Income were -$3.4 million (Q1 2026), -$5.0 million (Q4 2025), and -$3.1 million (Q3 2025) per Business Quant data.